Alexion Raises Outlook After Strong First Quarter
April 25 2019 - 7:28AM
Dow Jones News
By Bowdeya Tweh
Alexion Pharmaceuticals Inc. (ALXN) raised its profit and sales
outlook this year after posting stronger-than-expected
first-quarter results, bolstered by growth in Soliris and newer
treatments like Ultomiris.
Profit in the latest period more than doubled to $587.9 million,
or $2.61 a share.
Excluding one-time items, Alexion earned $2.39 a share. Analysts
polled by FactSet expected $2.21 a share.
Revenue rose 23%, to $1.14 billion, as analysts expected $1.13
billion.
For the full year Alexion expects per-share earnings of $6.76 to
$7.96, or $9.25 to $9.45 as adjusted, on revenue of $4.68 billion
to $4.75 billion. The company had expected per-share earnings of
$6.14 to $7.26, or $9.10 to $9.30 as adjusted, on $4.63 billion to
$4.7 billion in revenue.
Write to Bowdeya Tweh at bowdeya.tweh@wsj.com
(END) Dow Jones Newswires
April 25, 2019 07:13 ET (11:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Apr 2023 to Apr 2024